

## **Supplementary material**

---

*Matusik PS, Bryll A, Matusik PT, et al. Electrocardiography and cardiac magnetic resonance imaging in the detection of left ventricular hypertrophy: the impact of indexing methods. Kardiol Pol. 2020; 78: 889-898. doi: 10.33963/KP.15464*

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

### **Electrocardiography and cardiac magnetic resonance imaging in the detection of left ventricular hypertrophy: the impact of indexing methods**

**Brief title: ECG and CMR imaging in the detection of LVH**

**Patrycja S. Matusik<sup>1</sup>, Amira Bryll<sup>2</sup>, Paweł T. Matusik<sup>3,4</sup>,**

**Agnieszka Pac<sup>5</sup>, Tadeusz J. Popiela<sup>2</sup>**

<sup>1</sup> Department of Diagnostic Imaging, University Hospital, Kraków, Poland

<sup>2</sup> Department of Radiology, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland

<sup>3</sup> Department of Electrocardiology, Institute of Cardiology, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland

<sup>4</sup> Department of Electrocardiology, John Paul II Hospital, Kraków, Poland

<sup>5</sup> Chair of Epidemiology and Preventive Medicine, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland

#### **Address for correspondence:**

Paweł T. Matusik, MD, PhD, FEHRA,

Department of Electrocardiology, Institute of Cardiology, Faculty of Medicine, Jagiellonian University Medical College, John Paul II Hospital, ul. Prądnicka 80, 31-202 Kraków, Poland, phone: +48 12 614 22 77, email: [pawel.matusik@wp.eu](mailto:pawel.matusik@wp.eu)

**Supplementary Table S1.** Summary of electrocardiographic and cardiac magnetic resonance imaging criteria used for the diagnosis of left ventricular hypertrophy.

<b>ECG-LVH criteria</b>	<b>Cutoff values for the diagnosis of LVH</b>
R wave amplitude in V <sub>5</sub> or V <sub>6</sub>	> 2.6 mV [1]
Sokolow-Lyon voltage:  S wave amplitude in V <sub>1</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub>	> 3.5 mV [1]
Sokolow-Lyon product:  (S wave amplitude in V <sub>1</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> ) × QRS duration	≥ 371 mV × ms [2]
S wave amplitude in V <sub>2</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub>	> 4.5 mV [1]
R wave amplitude in aVL	> 1.1 mV [1]
R wave amplitude in aVL × QRS duration	> 103 mV × ms [3]
Cornell voltage:  R wave amplitude in aVL + S wave amplitude in V <sub>3</sub>	> 2.8 mV (M) or > 2 mV (F) [1]
Cornell (voltage-duration) product:  (R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> ) × QRS duration (M), (R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> + 0.8 mV) × QRS duration (F)	≥ 244 mV × ms [4]
Gubner-Ungerleider:  R wave amplitude in I + S wave amplitude in III	> 2.5 mV [1]
Peguero-Lo Presti:	≥ 2.3 mV (F) or ≥ 2.8 mV (M) [5]

S <sub>D</sub> (the deepest S-wave in any single lead) + S wave amplitude in V <sub>4</sub>	
<b>CMR-LVH criteria</b>	<b>Cutoff values for the diagnosis of LVH</b>
LVM	> 148 g (M) or > 96 g (F) [6]
%pLVM	> 1.31 [7-9]
LVM/BSA(MESA)	> 106.2 g/m <sup>2</sup> (M) or > 84.6 g/m <sup>2</sup> (F) [8, 10]
LVM/BSA	> 72 g/m <sup>2</sup> (M) or > 55 g/m <sup>2</sup> (F) [6]
LVM/height <sup>1.7</sup>	≥ 80 g/m <sup>1.7</sup> (M) or ≥ 60 g/m <sup>1.7</sup> (F) [8, 11]
LVM/height <sup>2.7</sup>	> 45.1 g/m <sup>2.7</sup> (M) or > 38 g/m <sup>2.7</sup> (F) [8, 10]

BSA – body surface area; ECG – electrocardiography; F– female; LVH – left ventricular hypertrophy;

LVM – left ventricular mass; M – male; MESA - Multi-Ethnic Study of Atherosclerosis; %pLVM – percent-predicted LVM.

**Supplementary Table S2.** Electrocardiographic criteria for the diagnosis of left ventricular hypertrophy parameters in patients with and without left ventricular hypertrophy based on percentage of predicted left ventricular mass.

<b>ECG-LVH criteria parameters</b>	<b>%pLVM &gt; 1.31; n = 6</b>	<b>%pLVM ≤ 1.31; n = 47</b>	<b>P value</b>
R wave amplitude in V <sub>5</sub> or V <sub>6</sub> , mV	1.1 ± 0.7	1.3 ± 0.6	0.41
S wave amplitude in V <sub>1</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> , mV	2.7 ± 1.2	2.1 ± 0.7	0.07
(S wave amplitude in V <sub>1</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> ) × QRS duration, mV × ms	262.9 ± 129.0	186.1 ± 73.7	<b>0.03</b>
S wave amplitude in V <sub>2</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> , mV	3.0 (2.2-4.2)	2.4 (1.9-3.1)	0.26
R wave amplitude in aVL, mV	0.7 (0.3-1.1)	0.3 (0.1-0.5)	0.07
R wave amplitude in aVL × QRS duration, mV × ms	63.8 (20.0-119.6)	27.5 (11.0-40.0)	0.07
R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> , mV	2.4 (1.4-2.8)	1.1 (0.8-1.7)	<b>0.01</b>
(R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> ) × QRS duration (M), (R wave amplitude in aVL + S wave	233.8 (166.0-303.9)	120.0 (64.0-184.0)	<b>0.003</b>

amplitude in $V_3 + 0.8 \text{ mV} \times$ QRS duration (F), $\text{mV} \times \text{ms}$			
R wave amplitude in I + S wave amplitude in III, mV	1.4 (0.6-2.1)	0.7 (0.5-1.1)	0.12
$S_D + S$ wave amplitude in $V_4$ , mV	3.4 (2.8-4.0)	2.0 (1.5-2.9)	<b>0.004</b>

Data are presented as mean  $\pm$  standard deviation or median (interquartile range). For abbreviations see the description of Supplementary Table S1.

**Supplementary Table S3.** Electrocardiographic criteria for the diagnosis of left ventricular hypertrophy parameters in patients with and without left ventricular hypertrophy based on left ventricular mass indexed by body surface area according to cutoff values proposed by Multi-Ethnic Study of Atherosclerosis.

<b>ECG-LVH criteria parameters</b>	<b>LVM/BSA (MESA) &gt; 106.2 g/m<sup>2</sup> (M) or &gt; 84.6 g/m<sup>2</sup> (F); n = 8</b>	<b>LVM/BSA (MESA) ≤ 106.2 g/m<sup>2</sup> (M) or ≤ 84.6 g/m<sup>2</sup> (F); n = 45</b>	<b>P value</b>
R wave amplitude in V <sub>5</sub> or V <sub>6</sub> , mV	1.2 ± 0.7	1.3 ± 0.6	0.74
S wave amplitude in V <sub>1</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> , mV	2.6 ± 1.1	2.1 ± 0.7	0.10
(S wave amplitude in V <sub>1</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> ) × QRS duration, mV × ms	251.7 ± 121.0	184.7 ± 72.5	<b>0.04</b>
S wave amplitude in V <sub>2</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> , mV	3.4 (2.2-4.1)	2.4 (1.9-3.1)	0.08
R wave amplitude in aVL, mV	0.5 (0.1-0.9)	0.3 (0.1-0.5)	0.38
R wave amplitude in aVL × QRS duration, mV × ms	41.8 (12.0-100.4)	28.0 (11.5-40.0)	0.34
R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> , mV	2.1 (1.5-2.7)	1.1 (0.8-1.7)	<b>0.004</b>
(R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> ) × QRS duration (M), (R wave amplitude in aVL + S wave amplitude in V <sub>3</sub>	206.3 (162.0-295.6)	116.0 (64.0-180.0)	<b>0.003</b>

+ 0.8 mV) × QRS duration (F), mV × ms			
R wave amplitude in I + S wave amplitude in III, mV	1.0 (0.5-1.8)	0.7 (0.5-1.1)	0.49
S <sub>D</sub> + S wave amplitude in V <sub>4</sub> , mV	3.4 (2.8-4.0)	2.0 (1.5-2.9)	< <b>0.001</b>

Data are presented as mean ± standard deviation or median (interquartile range). For abbreviations see the description of Supplementary Table S1.

**Supplementary Table S4.** Electrocardiographic criteria for the diagnosis of left ventricular hypertrophy parameters in patients with and without left ventricular hypertrophy based on left ventricular mass indexed by body surface area according to cutoff values proposed by Petersen et al. [6].

<b>ECG-LVH criteria parameters</b>	<b>LVM/BSA</b> <b>&gt; 72 g/m<sup>2</sup> (M) or</b> <b>&gt; 55 g/m<sup>2</sup> (F); n = 38</b>	<b>LVM/BSA</b> <b>≤ 72 g/m<sup>2</sup> (M) or</b> <b>≤ 55 g/m<sup>2</sup> (F); n = 15</b>	<b>P value</b>
R wave amplitude in V <sub>5</sub> or V <sub>6</sub> , mV	1.4 ± 0.6	1.2 ± 0.6	0.42
S wave amplitude in V <sub>1</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> , mV	2.3 (1.9-3.3)	2.1 (1.6-2.5)	0.06
(S wave amplitude in V <sub>1</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> ) × QRS duration, mV × ms	253.0 (148.0-308.0)	176.0 (132.0-239.1)	0.14
S wave amplitude in V <sub>2</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> , mV	3.0 (2.2-4.1)	2.4 (1.8-3.1)	0.25
R wave amplitude in aVL, mV	0.7 (0.2-0.9)	0.3 (0.1-0.5)	0.10
R wave amplitude in aVL × QRS duration, mV × ms	56.0 (16.0-93.5)	26.0 (11.3-40.0)	0.10
R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> , mV	1.5 ± 0.8	1.1 ± 0.5	0.12
(R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> ) × QRS duration (M), (R wave amplitude in aVL + S wave amplitude in V <sub>3</sub>	152.2 ± 86.7	110.2 ± 60.5	0.09



+ 0.8 mV) × QRS duration (F), mV × ms			
R wave amplitude in I + S wave amplitude in III, mV	1.2 (0.6-1.7)	0.7 (0.5-1.1)	0.46
S <sub>D</sub> + S wave amplitude in V <sub>4</sub> , mV	3.3 (2.6-3.9)	2.0 (1.5-2.9)	<b>0.04</b>

Data are presented as mean ± standard deviation or median (interquartile range). For abbreviations see the description of Supplementary Table S1.

**Supplementary Table S5.** Electrocardiographic criteria for the diagnosis of left ventricular hypertrophy parameters in patients with and without left ventricular hypertrophy based on left ventricular mass indexed by height<sup>1.7</sup> according to cutoff values proposed by Multi-Ethnic Study of Atherosclerosis.

<b>ECG-LVH criteria parameters</b>	<b>LVM/height<sup>1.7</sup> ≥ 80 g/m<sup>1.7</sup> (M) or ≥ 60 g/m<sup>1.7</sup> (F); n = 9</b>	<b>LVM/height<sup>1.7</sup> &lt; 80 g/m<sup>1.7</sup> (M) or &lt; 60 g/m<sup>1.7</sup> (F); n = 44</b>	<b>P value</b>
R wave amplitude in V <sub>5</sub> or V <sub>6</sub> , mV	1.2 ± 0.6	1.3 ± 0.6	0.70
S wave amplitude in V <sub>1</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> , mV	2.6 ± 1.0	2.1 ± 0.7	0.10
(S wave amplitude in V <sub>1</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> ) × QRS duration, mV × ms	251.8 ± 113.2	183.1 ± 72.6	<b>0.02</b>
S wave amplitude in V <sub>2</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> , mV	3.0 (2.2-4.1)	2.4 (1.8-3.1)	0.18
R wave amplitude in aVL, mV	0.7 (0.2-0.9)	0.3 (0.1-0.5)	0.20
R wave amplitude in aVL × QRS duration, mV × ms	56.0 (16.0-93.5)	26.0 (11.3-40.0)	0.16
R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> , mV	2.1 (1.3-2.7)	1.1 (0.8-1.7)	<b>0.02</b>
(R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> ) × QRS duration (M), (R wave amplitude in aVL + S wave amplitude in V <sub>3</sub>	176.0 (164.0-294.3)	112.0 (64.0-176.0)	<b>0.002</b>

+ 0.8 mV) × QRS duration (F), mV × ms			
R wave amplitude in I + S wave amplitude in III, mV	1.2 (0.6-1.7)	0.7 (0.5-1.1)	0.26
S <sub>D</sub> + S wave amplitude in V <sub>4</sub> , mV	3.3 (2.6-3.9)	2.0 (1.5-2.9)	<b>0.004</b>

Data are presented as mean ± standard deviation or median (interquartile range). For abbreviations see the description of Supplementary Table S1.

**Supplementary Table S6.** Electrocardiographic criteria for the diagnosis of left ventricular hypertrophy parameters in patients with and without left ventricular hypertrophy based on left ventricular mass indexed by  $\text{height}^{2.7}$  according to cutoff values proposed by Multi-Ethnic Study of Atherosclerosis.

<b>ECG-LVH criteria parameters</b>	<b>LVM/height<sup>2.7</sup></b> <b>&gt; 45.1 g/m<sup>2.7</sup> (M) or</b> <b>&gt; 38 g/m<sup>2.7</sup> (F); n = 8</b>	<b>LVM/height<sup>2.7</sup></b> <b>≤ 45.1 g/m<sup>2.7</sup> (M) or</b> <b>≤ 38 g/m<sup>2.7</sup> (F); n = 45</b>	<b>P value</b>
R wave amplitude in V <sub>5</sub> or V <sub>6</sub> , mV	1.1 ± 0.6	1.3 ± 0.6	0.35
S wave amplitude in V <sub>1</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> , mV	2.5 ± 1.1	2.1 ± 0.7	0.17
(S wave amplitude in V <sub>1</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> ) × QRS duration, mV × ms	244.8 ± 118.9	185.9 ± 74.1	0.07
S wave amplitude in V <sub>2</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> , mV	2.6 (2.1-4.0)	2.4 (1.9-3.2)	0.38
R wave amplitude in aVL, mV	0.7 (0.2-0.9)	0.3 (0.1-0.5)	0.14
R wave amplitude in aVL × QRS duration, mV × ms	63.8 (12.0-101.8)	27.5 (11.5-40.0)	0.14
R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> , mV	1.9 (2.7-1.3)	1.1 (0.8-1.8)	<b>0.03</b>
(R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> ) × QRS duration (M), (R wave amplitude in aVL + S wave amplitude in V <sub>3</sub>	176.0 (162.0-295.6)	116.0 (64.0-184.0)	<b>0.005</b>

+ 0.8 mV) × QRS duration (F), mV × ms			
R wave amplitude in I + S wave amplitude in III, mV	1.4 (0.5-1.8)	0.7 (0.5-1.1)	0.20
S <sub>D</sub> + S wave amplitude in V <sub>4</sub> , mV	3.4 (2.6-4.0)	2.0 (1.6-2.9)	<b>0.01</b>

Data are presented as mean ± standard deviation or median (interquartile range). For abbreviations see the description of Supplementary Table S1.

**Supplementary Table S7.** Electrocardiographic criteria for the diagnosis of left ventricular hypertrophy in patients with and without left ventricular hypertrophy based on percentage of predicted left ventricular mass.

Positive ECG-LVH criteria	%pLVM > 1.31; n = 6		%pLVM ≤ 1.31; n = 47		McNemar test <sup>#</sup>	P value
	TP	FN	FP	TN		
R wave amplitude in V <sub>5</sub> or V <sub>6</sub> > 2.6 mV	0 (0.0%)	6 (100.0%)	1 (2.1%)	46 (97.9%)	<b>0.13</b>	1*
S wave amplitude in V <sub>1</sub> + R wave amplitude V <sub>5</sub> or V <sub>6</sub> > 3.5 mV	2 (33.3%)	4 (66.7%)	2 (4.3%)	45 (95.7%)	<b>0.69</b>	0.06*
(S wave amplitude in V <sub>1</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> ) × QRS duration ≥ 371 mV × ms	1 (16.7%)	5 (83.3%)	0 (0.0%)	47 (100.0%)	<b>0.06</b>	0.11*
S wave amplitude in V <sub>2</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> > 4.5 mV	0 (0.0%)	6 (100.0%)	2 (4.3%)	45 (95.7%)	<b>0.29</b>	1*
R wave amplitude in aVL > 1.1 mV	1 (16.7%)	5 (83.3%)	2 (4.3%)	45 (95.7%)	<b>0.45</b>	0.31*
R wave amplitude in aVL × QRS duration > 103 mV × ms	2 (33.3%)	4 (66.7%)	2 (4.3%)	45 (95.7%)	<b>0.69</b>	0.06*
R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> > 2.8 m (M) or > 2 mV (F)	1 (16.7%)	5 (83.3%)	1 (2.1%)	46 (97.9%)	<b>0.22</b>	0.22*

(R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> ) × QRS duration (M), (R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> + 0.8 mV) × QRS duration (F) ≥244 mV × ms	3 (50.0%)	3 (50.0%)	2 (4.3%)	45 (95.7%)	<b>1</b>	<b>0.008*</b>
R wave amplitude in I + S wave amplitude in III >2.5 mV	0 (0.0%)	6 (100.0%)	1 (2.1%)	46 (97.9%)	<b>0.13</b>	1*
S <sub>D</sub> + S wave amplitude in V <sub>4</sub> ≥2.3 mV (F) or ≥2.8 mV (M)	6 (100.0%)	0 (0.0%)	18 (38.3%)	29 (61.7%)	< 0.001	<b>0.006*</b>
At least one positive ECG-LVH criterion	6 (100.0%)	0 (0.0%)	20 (42.6%)	27 (57.4%)	< 0.001	<b>0.01*</b>

Data are presented as number (percentage). \*Fisher exact test (exact significance, 2-tailed). FN – false negative; FP – false positive; TN – true negative; TP – true positive. For other abbreviations see the description of Supplementary Table S1.

**Supplementary Table S8.** Electrocardiographic criteria for the diagnosis of left ventricular hypertrophy in patients with and without left ventricular hypertrophy based on left ventricular mass indexed by body surface area according to cutoff values proposed by Petersen et al. [6].

Positive ECG-LVH criteria	LVM/BSA > 72 g/m <sup>2</sup> (M) or > 55 g/m <sup>2</sup> (F); n = 38		LVM/BSA ≤ 72 g/m <sup>2</sup> (M) or ≤ 55 g/m <sup>2</sup> (F); n = 15		McNemar test <sup>#</sup>	P value
	TP	FN	FP	TN		
R wave amplitude in V <sub>5</sub> or V <sub>6</sub> > 2.6 mV	1 (2.6%)	37 (97.4%)	0 (0.0%)	15 (100.0%)	< 0.001	1*
S wave amplitude in V <sub>1</sub> + R wave amplitude V <sub>5</sub> or V <sub>6</sub> > 3.5 mV	3 (7.9%)	35 (92.1%)	1 (6.7%)	14 (93.3%)	< 0.001	1*
(S wave amplitude in V <sub>1</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> ) × QRS duration ≥ 371 mV × ms	1 (2.6%)	37 (97.4%)	0 (0.0%)	15 (100.0%)	< 0.001	1*
S wave amplitude in V <sub>2</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> > 4.5 mV	2 (5.3%)	36 (94.7%)	0 (0.0%)	15 (100.0%)	< 0.001	1*
R wave amplitude in aVL > 1.1 mV	3 (7.9%)	35 (92.1%)	0 (0.0%)	15 (100.0%)	< 0.001	0.55*



R wave amplitude in aVL × QRS duration >103 mV × ms	4 (10.5%)	34 (89.5%)	0 (0.0%)	15 (100.0%)	< 0.001	0.57*
R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> >2.8 m (M) or >2 mV (F)	2 (5.3%)	36 (94.7%)	0 (0.0%)	15 (100.0%)	< 0.001	1*
(R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> ) × QRS duration (M), (R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> + 0.8 mV) × QRS duration (F) ≥244 mV × ms	5 (13.2%)	33 (86.8%)	0 (0.0%)	15 (100.0%)	< 0.001	0.31*
R wave amplitude in I + S wave amplitude in III >2.5 mV	1 (2.6%)	37 (97.4%)	0 (0.0%)	15 (100.0%)	< 0.001	1*
S <sub>D</sub> + S wave amplitude in V <sub>4</sub> ≥2.3 mV (F) or ≥2.8 mV (M)	21 (55.3%)	17 (44.7%)	3 (20.0%)	12 (80.0%)	0.003	<b>0.02</b>
At least one positive ECG-LVH criterion	22 (57.9%)	16 (42.1%)	4 (26.7%)	11 (73.3%)	0.01	<b>0.04</b>

Data are presented as number (percentage). \*Fisher exact test (exact significance, 2-tailed). For abbreviations see the description of Supplementary Table S1 and S7.

**Supplementary Table S9.** Electrocardiographic criteria for the diagnosis of left ventricular hypertrophy in patients with and without left ventricular hypertrophy based on left ventricular mass indexed by body surface area according to cutoff values proposed by Multi-Ethnic Study of Atherosclerosis.

Positive ECG-LVH criteria	LVM/BSA (MESA) > 106.2 g/m <sup>2</sup> (M) or > 84.6 g/m <sup>2</sup> (F); n = 8		LVM/BSA (MESA) ≤ 106.2 g/m <sup>2</sup> (M) or ≤ 84.6 g/m <sup>2</sup> (F); n = 45		McNemar test <sup>#</sup>	P value
	TP	FN	FP	TN		
R wave amplitude in V <sub>5</sub> or V <sub>6</sub> >2.6 mV	0 (0.0%)	8 (100.0%)	1 (2.2%)	44 (97.8%)	0.04	1*
S wave amplitude in V <sub>1</sub> + R wave amplitude V <sub>5</sub> or V <sub>6</sub> >3.5 mV	2 (25.0%)	6 (75.0%)	2 (4.4%)	43 (95.6%)	<b>0.29</b>	0.1*
(S wave amplitude in V <sub>1</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> ) × QRS duration ≥371 mV × ms	1 (12.5%)	7 (87.5%)	0 (0.0%)	45 (100.0%)	0.02	0.15*
S wave amplitude in V <sub>2</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> >4.5 mV	0 (0.0%)	8 (100.0%)	2 (4.4%)	43 (95.6%)	<b>0.11</b>	1*
R wave amplitude in aVL >1.1 mV	1 (12.5%)	7 (87.5%)	2 (4.4%)	43 (95.6%)	<b>0.18</b>	0.39*
R wave amplitude in aVL × QRS duration >103 mV × ms	2 (25.0%)	6 (75.0%)	2 (4.4%)	43 (95.6%)	<b>0.29</b>	0.1

R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> >2.8 m (M) or >2 mV (F)	1 (12.5%)	7 (87.5%)	1 (2.2%)	44 (97.8%)	<b>0.07</b>	0.28*
(R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> ) × QRS duration (M), (R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> + 0.8 mV) × QRS duration (F) ≥244 mV × ms	3 (37.5%)	5 (62.5%)	2 (4.4%)	43 (95.6%)	<b>0.45</b>	<b>0.02*</b>
R wave amplitude in I + S wave amplitude in III >2.5 mV	0 (0.0%)	8 (100.0%)	1 (2.2%)	44 (97.8%)	0.04	1*
S <sub>D</sub> + S wave amplitude in V <sub>4</sub> ≥2.3 mV (F) or ≥2.8 mV (M)	8 (100.0%)	0 (0.0%)	16 (35.6%)	29 (64.4%)	< 0.001	<b>0.001*</b>
At least one positive ECG- LVH criterion	8 (100.0%);	0 (0.0%)	18 (40.0%)	27 (60.0%)	< 0.001	<b>0.002</b>

Data are presented as number (percentage). \*Fisher exact test (exact significance, 2-tailed). For abbreviations see the description of Supplementary Table S1 and S7.

**Supplementary Table S10.** Electrocardiographic criteria for the diagnosis of left ventricular hypertrophy in patients with and without left ventricular hypertrophy based on left ventricular mass indexed by height<sup>1.7</sup> according to cutoff values proposed by Multi-Ethnic Study of Atherosclerosis.

Positive ECG-LVH criteria	LVM/height <sup>1.7</sup> ≥ 80 g/m <sup>1.7</sup> (M) or ≥ 60 g/m <sup>1.7</sup> (F); n = 9		LVM/height <sup>1.7</sup> < 80 g/m <sup>1.7</sup> (M) or < 60 g/m <sup>1.7</sup> (F); n = 44		McNemar test <sup>#</sup>	P value
	TP	FN	FP	TN		
R wave amplitude in V <sub>5</sub> or V <sub>6</sub> >2.6 mV	0 (0.0%)	9 (100.0%)	1 (2.3%)	43 (97.7%)	0.02	1*
S wave amplitude in V <sub>1</sub> + R wave amplitude V <sub>5</sub> or V <sub>6</sub> >3.5 mV	2 (22.2%)	7 (77.8%)	2 (4.5%)	42 (95.5%)	<b>0.2</b>	0.13*
(S wave amplitude in V <sub>1</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> ) × QRS duration ≥371 mV × ms	1 (11.1%)	8 (88.9%)	0 (0.0%)	44 (100.0%)	0.008	0.17*
S wave amplitude in V <sub>2</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> >4.5 mV	0 (0.0%)	9 (100.0%)	2 (4.5%)	42 (95.5%)	<b>0.07</b>	1*
R wave amplitude in aVL >1.1 mV	1 (11.1%)	8 (88.9%)	2 (4.5%)	42 (95.5%)	<b>0.1</b>	0.44*
R wave amplitude in aVL × QRS duration >103 mV × ms	2 (22.2%)	7 (77.8%)	2 (4.5%)	42 (95.5%)	<b>0.2</b>	0.13*

R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> >2.8 m (M) or >2 mV (F)	1 (11.1%)	8 (88.9%)	1 (2.3%)	43 (97.7%)	0.04	0.31*
(R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> ) × QRS duration (M), (R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> + 0.8 mV) × QRS duration (F) ≥244 mV × ms	3 (33.3%)	6 (66.7%)	2 (4.5%)	42 (95.5%)	<b>0.29</b>	<b>0.03*</b>
R wave amplitude in I + S wave amplitude in III >2.5 mV	0 (0.0%)	9 (100.0%)	1 (2.3%)	43 (97.7%)	0.02	1*
S <sub>D</sub> + S wave amplitude in V <sub>4</sub> ≥2.3 mV (F) or ≥2.8 mV (M)	8 (88.9%)	1 (11.1%)	16 (36.4%)	28 (63.6%)	< 0.001	<b>0.007*</b>
At least one positive ECG-LVH criterion	8 (88.9%)	1 (11.1%)	18 (40.9%)	26 (59.1%)	< 0.001	<b>0.01*</b>

Data are presented as number (percentage). \*Fisher exact test (exact significance, 2-tailed). For abbreviations see the description of Supplementary Table S1 and S7.

**Supplementary Table S11.** Electrocardiographic criteria for the diagnosis of left ventricular hypertrophy in patients with and without left ventricular hypertrophy based on left ventricular mass indexed by height<sup>2.7</sup> according to cutoff values proposed by Multi-Ethnic Study of Atherosclerosis.

Positive ECG-LVH criteria	LVM/height <sup>2.7</sup> > 45.1 g/m <sup>2.7</sup> (M) or > 38 g/m <sup>2.7</sup> (F); n = 8		LVM/height <sup>2.7</sup> ≤ 45.1 g/m <sup>2.7</sup> (M) or ≤ 38 g/m <sup>2.7</sup> (F); n = 45		McNemar test <sup>#</sup>	P value
	TP	FN	FP	TN		
R wave amplitude in V <sub>5</sub> or V <sub>6</sub> >2.6 mV	0 (0.0%)	8 (100.0%)	1 (2.2%)	44 (97.8%)	0.04	1*
S wave amplitude in V <sub>1</sub> + R wave amplitude V <sub>5</sub> or V <sub>6</sub> >3.5 mV	2 (25.0%)	6 (75.0%)	2 (4.4%)	43 (95.6%)	<b>0.29</b>	0.1*
(S wave amplitude in V <sub>1</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> ) × QRS duration ≥371 mV × ms	1 (12.5%)	7 (87.5%)	0 (0.0%)	45 (100.0%)	0.02	0.15*
S wave amplitude in V <sub>2</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> >4.5 mV	0 (0.0%)	8 (100.0%)	2 (4.4%)	43 (95.6%)	<b>0.12</b>	1*
R wave amplitude in aVL >1.1 mV	1 (12.5%)	7 (87.5%)	2 (4.4%)	43 (95.6%)	<b>0.18</b>	0.39

R wave amplitude in aVL × QRS duration >103 mV × ms	2 (25.0%)	6 (75.0%)	2 (4.4%)	43 (95.6%)	<b>0.29</b>	0.1*
R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> >2.8 m (M) or >2 mV (F)	1 (12.5%)	7 (87.5%)	1 (2.2%)	44 (97.8%)	0.07	0.28*
(R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> ) × QRS duration (M), (R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> + 0.8 mV) × QRS duration (F) ≥244 mV × ms	3 (37.5%)	5 (62.5%)	2 (4.4%)	43 (95.6%)	<b>0.45</b>	<b>0.02*</b>
R wave amplitude in I + S wave amplitude in III >2.5 mV	0 (0.0%)	8 (100.0%)	1 (2.2%)	44 (97.8%)	0.04	1*
S <sub>D</sub> + S wave amplitude in V <sub>4</sub> ≥2.3 mV (F) or ≥2.8 mV (M)	7 (87.5%)	1 (12.5%)	17 (37.8%)	28 (62.2%)	< 0.001	<b>0.02*</b>
At least one positive ECG-LVH criterion	7 (87.5%)	1 (12.5%)	19 (42.2%)	26 (57.8%)	< 0.001	<b>0.02*</b>

Data are presented as number (percentage). \*Fisher exact test (exact significance, 2-tailed). For abbreviations see the description of Supplementary Table S1 and S7.

**Supplementary Table S12.** Correlations between electrocardiographic criteria for the diagnosis of left ventricular hypertrophy parameters and left ventricular mass, according to indexed and non-indexed left ventricular mass.

<b>ECG-LVH criteria parameters</b>	<b>LVM (g)</b>	<b>%pLVM</b>	<b>LVM/BSA (g/m<sup>2</sup>)</b>	<b>LVM/height<sup>1.7</sup> (g/m<sup>1.7</sup>)</b>	<b>LVM/height<sup>2.7</sup> (g/m<sup>2.7</sup>)</b>
R wave amplitude in V <sub>5</sub> or V <sub>6</sub> , mV	0.12* ( <i>P</i> = 0.41)	0.15* ( <i>P</i> = 0.30)	0.17* ( <i>P</i> = 0.22)	0.09* ( <i>P</i> = 0.52)	0.07* ( <i>P</i> = 0.63)
S wave amplitude in V <sub>1</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> , mV	0.24 ( <i>P</i> = 0.09)	<b>0.31 (<i>P</i> = 0.02)</b>	<b>0.30 (<i>P</i> = 0.03)</b>	<b>0.30 (<i>P</i> = 0.03)</b>	<b>0.28 (<i>P</i> = 0.04)</b>
(S wave amplitude in V <sub>1</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> ) × QRS duration, mV × ms	<b>0.27 (<i>P</i> &lt; 0.05)</b>	<b>0.31 (<i>P</i> = 0.02)</b>	<b>0.32 (<i>P</i> = 0.02)</b>	<b>0.33 (<i>P</i> = 0.02)</b>	<b>0.31 (<i>P</i> = 0.02)</b>
S wave amplitude in V <sub>2</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> , mV	0.33 ( <i>P</i> = 0.01)	0.28 ( <i>P</i> = 0.04)	0.34 ( <i>P</i> = 0.01)	<b>0.28 (<i>P</i> &lt; 0.05)</b>	0.22 ( <i>P</i> = 0.12)
R wave amplitude in aVL, mV	0.27 ( <i>P</i> = 0.05)	0.28 ( <i>P</i> = 0.04)	0.26 ( <i>P</i> = 0.06)	<b>0.36 (<i>P</i> = 0.009)</b>	<b>0.37 (<i>P</i> = 0.006)</b>
R wave amplitude in aVL × QRS duration, mV × ms	<b>0.27 (<i>P</i> &lt; 0.05)</b>	<b>0.28 (<i>P</i> &lt; 0.05)</b>	<b>0.27 (<i>P</i> &lt; 0.05)</b>	<b>0.37 (<i>P</i> = 0.007)</b>	<b>0.39 (<i>P</i> = 0.004)</b>



R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> , mV	<b>0.36 (P = 0.008)</b>	<b>0.33 (P = 0.02)</b>	<b>0.36 (P = 0.007)</b>	0.37 (P = 0.007)	0.38 (P = 0.005)
(R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> ) × QRS duration (M), (R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> + 0.8 mV) × QRS duration (F), mV × ms	0.24 (P = 0.09)	<b>0.34 (P = 0.01)</b>	<b>0.29 (P = 0.04)</b>	0.32 (P = 0.02)	0.38 (P = 0.005)
R wave amplitude in I + S wave amplitude in III, mV	0.21 (P = 0.14)	0.21 (P = 0.13)	0.20 (P = 0.15)	<b>0.30 (P = 0.03)</b>	<b>0.31 (P = 0.03)</b>
S <sub>D</sub> + S wave amplitude in V <sub>4</sub> , mV	<b>0.46 (P = 0.001)</b>	<b>0.48 (P &lt; 0.001)</b>	<b>0.50 (P &lt; 0.001)</b>	<b>0.44 (P = 0.001)</b>	<b>0.43 (P = 0.001)</b>

Data are presented as Pearson correlation coefficient\* or Spearman rank correlation coefficient (*P* value). %pLVM – percent-predicted LVM. For other abbreviations see the description of Supplementary Table S1.

**Supplementary Table S13.** Positive predictive value, negative predictive value, accuracy and negative likelihood ratio of electrocardiographic criteria for the diagnosis of left ventricular hypertrophy. Data are shown for indexed and non-indexed left ventricular mass.

<b>ECG-LVH criteria</b>	<b>Indexed and non-indexed LVM</b>	<b>PPV (%) (95% CI)</b>	<b>NPV (%) (95% CI)</b>	<b>Accuracy (%) (95% CI)</b>	<b>NLR (95% CI)</b>
R wave amplitude in V <sub>5</sub> or V <sub>6</sub> > 2.6 mV	LVM;	100.0; (*)	32.7 (31.5-33.9);	34.0 (21.5-48.3);	1.0 (0.9 -1.0);
	LVM/BSA (MESA);	0.0; (*)	84.6 (84.0-85.2);	83.0 (70.2-91.9);	1.0 (1.0-1.1);
	LVM/BSA;	100.0; (*)	28.9 (27.8-29.9);	30.2 (18.3-44.3);	1.0 (0.9 -1.0);
	LVM / height <sup>1.7</sup> ;	0.0; (*)	82.7 (82.0-83.3);	81.1 (68.0-90.6);	1.0 (1.0-1.1);
	LVM / height <sup>2.7</sup> ;	0.0; (*)	84.6 (84.0-85.2);	83.0 (70.2-91.9);	1.0 (1.0-1.1);
	%pLVH.	0.0. (*)	88.5 (88.0-88.9).	86.8 (74.7-94.5).	1.0 (1.0-1.1).
S wave amplitude in V <sub>1</sub> + R wave amplitude V <sub>5</sub> or V <sub>6</sub> > 3.5 mV	LVM;	75.0 (25.2-96.4);	32.7 (29.4-36.1);	35.8 (23.1-50.2);	1.0 (0.8-1.1);
	LVM/BSA (MESA);	50.0 (14.1-85.9);	87.8 (82.7-91.5);	84.9 (72.4-93.3);	0.8 (0.5-1.2);
	LVM/BSA;	75.0 (25.3-96.4);	28.6 (25.3-32.0);	32.1 (19.9-46.3);	1.0 (0.8-1.2);
	LVM/ height <sup>1.7</sup> ;	50.0 (13.9-86.1);	85.7 (80.8-89.5);	83.0 (70.2-91.9);	0.8 (0.6-1.2);
	LVM / height <sup>2.7</sup> ;	50.0 (14.1-85.9);	87.8 (82.7-91.5);	84.9 (72.4-93.3);	0.8 (0.5-1.2);
	%pLVH.	50.0 (14.6-85.4).	91.8 (86.4-95.2).	88.7 (77.0-95.7).	0.7 (0.4-1.2).
(S wave amplitude in V <sub>1</sub> + R wave amplitude in	LVM;	100.0; (*)	32.7 (31.5-33.9);	34.0 (21.5-48.3);	1.0 (0.9 -1.0);
	LVM/BSA (MESA);	100.0; (*)	86.5 (83.2-89.3);	86.8 (74.4-94.5);	0.9 (0.7-1.1);


V <sub>5</sub> or V <sub>6</sub> × QRS duration ≥371 mV × ms	LVM/BSA;	100.0 (*);	28.9 (27.8-29.9);	30.2 (18.3-44.3);	1.0 (0.9 -1.0);
	LVM / height <sup>1.7</sup> ;	100.0 (*);	84.6 (81.4-87.4);	84.9 (81.4-87.4);	0.9 (0.7-1.1);
	LVM / height <sup>2.7</sup> ;	100.0 (*);	86.5 (83.2-89.3);	86.8 (74.7-94.5);	0.9 (0.7-1.1);
	%pLVH.	100.0 (*).	90.4 (86.8-93.1).	90.6 (79.3-96.9).	0.8 (0.6-1.2).
S wave amplitude in V <sub>2</sub> + R wave amplitude in V <sub>5</sub> or V <sub>6</sub> >4.5 mV	LVM;	50.0 (6.2-93.8);	31.4 (28.6-34.3);	32.1 (19.9-46.3);	1.0 (0.9-1.2);
	LVM/BSA (MESA);	0.0 (*);	84.3 (83.4-85.1);	81.0 (68.0-90.6);	1.1 (1.00-1.1);
	LVM/BSA;	100.0 (*);	29.4 (27.9-31.0);	32.1 (19.9-46.3);	1.0 (0.9-1.0);
	LVM / height <sup>1.7</sup> ;	0.0 (*);	82.4 (81.4-83.3);	79.3 (65.9-89.2);	1.1 (1.0-1.1);
	LVM / height <sup>2.7</sup> ;	0.0 (*);	84.3 (83.5-85.1);	81.1 (68.0-90.6);	1.1 (1.0-1.1);
	%pLVH.	0.0 (*).	88.2 (87.6-88.9).	84.9 (72.4-93.3).	1.0 (1.0-1.1).
R wave amplitude in aVL >1.1 mV	LVM;	100.0 (*);	34.0 (31.8-36.2);	37.7 (24.8-52.1);	0.9 (0.8-1.0);
	LVM/BSA (MESA);	33.3 (4.9-83.0);	86.0 (82.4-88.9);	83.0 (70.2-91.9);	0.9 (0.7-1.2);
	LVM/BSA;	100.0 (*);	30.0 (28.1-32.0);	34.0 (21.5-48.3);	0.9 (0.8-1.0);
	LVM / height <sup>1.7</sup> ;	33.3 (4.8-83.2);	84.0 (80.5-87.0);	81.1 (68.0-90.6);	0.9 (0.7-1.2);
	LVM / height <sup>2.7</sup> ;	33.3 (4.9-83.0);	86.0 (82.4-88.9);	83.0 (70.2-91.9);	0.9 (0.7-1.2);
	%pLVH.	33.3 (5.0-82.5).	90.0 (86.2-92.8).	86.8 (74.7-94.5).	0.9 (0.6-1.3).
R wave amplitude in aVL × QRS duration >103 mV × ms	LVM;	100.0 (*);	34.7 (32.1-37.4);	39.6 (26.5-54.0);	0.9 (0.8-1.0);
	LVM/BSA (MESA);	50.0 (14.1-85.9);	87.8 (82.7-91.5);	84.9 (72.4-93.3);	0.8 (0.5-1.2);

	LVM/BSA;	100.0 (*);	30.6 (28.4-33.0);	35.8 (23.1-50.2);	0.9 (0.8-1.0);
	LVM / height <sup>1.7</sup> ;	50.0 (13.9-86.1);	85.7 (80.8-89.5);	83.0 (70.2-91.9);	0.8 (0.6-1.2);
	LVM / height <sup>2.7</sup> ;	50.0 (14.1-85.9);	87.8 (82.7-91.5);	84.9 (72.4-93.3);	0.8 (0.5-1.2);
	%pLVH.	50.0 (14.6-85.4).	91.8 (86.4-95.2).	88.7 (77.0-95.7).	0.7 (0.4-1.2).
R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> >2.8 m (M) or >2 mV (F)	LVM;	100.0 (*)	33.3 (31.6-35.1);	35.8 (23.1-50.2);	0.9 (0.9-1.0);
	LVM/BSA (MESA);	50.0 (6.5-93.5);	86.3 (82.8-89.1);	84.9 (72.4-93.3);	0.9 (0.7-1.2);
	LVM/BSA;	100.0 (*);	29.4 (27.9-31.0);	32.1 (19.9-46.3);	0.9 (0.9-1.0);
	LVM / height <sup>1.7</sup> ;	50.0 (6.4-93.6);	84.3 (80.9-87.2);	83.0 (70.2-91.9);	0.9 (0.7-1.2);
	LVM / height <sup>2.7</sup> ;	50.0 (6.5-93.5);	86.3 (82.8-89.1);	84.9 (72.4-93.3);	0.9 (0.7-1.2);
	%pLVH.	50.0 (6.7-93.3).	90.2 (86.5-93.0).	88.7 (77.0-95.7).	0.9 (0.6-1.2).
(R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> ) × QRS duration (M), (R wave amplitude in aVL + S wave amplitude in V <sub>3</sub> + 0.8 mV) × QRS duration (F) ≥244 mV × ms	LVM;	100.0 (*);	35.4 (32.5-38.5);	41.5 (28.1-55.9);	0.9 (0.8-1.0);
	LVM/BSA (MESA);	60.0 (22.8-88.4);	89.6 (83.4-93.7);	86.8 (74.7-94.5);	0.7 (0.4-1.1);
	LVM/BSA;	100.0 (*);	31.3 (28.7-34.0);	37.7 (24.8-52.1);	0.9 (0.8-1.0);
	LVM / height <sup>1.7</sup> ;	60.0 (22.6-88.5);	87.5 (81.5-91.8);	84.9 (72.4-93.3);	0.7 (0.4-1.1);
	LVM / height <sup>2.7</sup> ;	60.0 (22.8-88.4);	89.6 (83.4-93.7);	86.8 (74.7-94.5);	0.7 (0.4-1.1);
	%pLVH.	60.0 (23.7-87.9).	93.8 (87.1-97.1).	90.6 (79.3-96.9).	0.5 (0.2-1.2).
R wave amplitude in I + S wave amplitude in III >2.5 mV	LVM;	100.0 (*);	32.7 (31.5-33.9);	34.0 (21.5-48.3);	1.0 (0.9-1.0);
	LVM/BSA (MESA);	0.0 (*);	84.6 (84.0-85.2);	83.0 (70.2-91.9);	1.0 (1.0-1.1);


	LVM/BSA;	100.0 (*);	28.9 (27.8-29.9);	30.2 (18.3-44.3);	1.0 (0.9-1.0);
	LVM / height <sup>1.7</sup> ;	0.0 (*);	82.7 (82.0-83.3);	81.1 (68.0-90.6);	1.0 (1.0-1.1);
	LVM / height <sup>2.7</sup> ;	0.0 (*);	84.6 (84.0-85.2);	83.0 (70.2-91.9);	1.0 (1.0-1.1);
	%pLVH.	0.0 (*).	88.5 (88.0-88.9).	86.8 (74.7-94.5).	1.0 (1.0-1.1).
S <sub>D</sub> + S wave amplitude in V <sub>4</sub> ≥2.3 mV (F) or ≥2.8 mV (M)	LVM;	87.5 (70.7-95.3);	48.3 (37.4-59.3);	66.0 (51.7-78.5);	0.5 (0.3-0.8)
	LVM/BSA (MESA);	33.3 (25.2-42.6);	100.0 (*);	69.8 (55.7-81.7);	0.0 (0.0-0.0);
	LVM/BSA;	87.5 (71.0-95.3);	41.4 (31.4-52.2);	62.3 (47.9-75.2);	0.6 (0.4-0.9);
	LVM / height <sup>1.7</sup> ;	33.3 (24.1-44.1);	96.6 (81.3-99.5);	67.9 (53.7-80.1);	0.2 (0.0-1.1);
	LVM / height <sup>2.7</sup> ;	29.2 (20.7-39.4);	96.6 (81.5-99.4);	66.0 (51.7-78.5);	0.2 (0.0-1.3);
	%pLVH.	25.0 (18.8-32.4).	100.0 (*).	66.0 (51.7-78.5).	0.0 (0.0-0.0).
At least one positive ECG-LVH criterion	LVM;	84.6 (36.3-60.2);	48.2 (36.3-60.2);	66.0 (51.7-78.5);	0.5 (0.3-0.8);
	LVM/BSA (MESA);	30.8 (23.7-38.9);	100.0 (*);	66.0 (51.7-78.5);	0.0 (0.0-0.0);
	LVM/BSA;	84.6 (69.5-93.0);	40.7 (29.8-52.7);	62.3 (47.9-75.2);	0.6 (0.4-0.9);
	LVM / height <sup>1.7</sup> ;	30.8 (22.5-40.4);	96.3 (80.1-99.4);	64.2 (49.8-76.9);	0.2 (0.0-1.2);
	LVM / height <sup>2.7</sup> ;	26.9 (19.3-36.2);	96.3 (80.3-99.4);	62.3 (47.9-75.2);	0.2 (0.0-1.4);
	%pLVH.	23.1 (17.7-29.5).	100.0 (*).	62.3 (47.9-75.2).	0.0 (0.0-0.0).

Data are presented as percentage (95% CI) or number (95% CI). (\*)- 95% CI not available. CI – confidence interval; MESA - Multi-Ethnic Study of Atherosclerosis; NLR- negative likelihood ratio; NPV – negative predictive value; PPV – positive predictive value. For other abbreviations see the description of Supplementary Table S1.


**Supplementary Figure S1.** Area under the curve of ECG-LVH criteria parameters representing the predictive performance of left ventricular hypertrophy based on percentage of predicted left ventricular mass.



**Supplementary Figure S2.** Area under the curve of ECG-LVH criteria parameters representing the predictive performance of left ventricular hypertrophy based on left ventricular mass indexed by body surface area according to cutoff values proposed by Multi-Ethnic Study of Atherosclerosis.




**Supplementary Figure S3.** Area under the curve of ECG-LVH criteria parameters representing the predictive performance of left ventricular hypertrophy based on left ventricular mass indexed by body surface area according to cutoff values proposed by Petersen et al. [6].






**Supplementary Figure S4.** Area under the curve of ECG-LVH criteria parameters representing the predictive performance of left ventricular hypertrophy based on left ventricular mass indexed by  $\text{height}^{1.7}$  according to cutoff values proposed by Multi-Ethnic Study of Atherosclerosis.



**Supplementary Figure S5.** Area under the curve of ECG-LVH criteria parameters representing the predictive performance of left ventricular hypertrophy based on left ventricular mass indexed by  $\text{height}^{2.7}$  according to cutoff values proposed by Multi-Ethnic Study of Atherosclerosis.



## Supplementary references

1. Baranowski, R., et al., [*Electrocardiographic criteria for diagnosis of the heart chamber enlargement, necrosis and repolarisation abnormalities including acute coronary syndromes. Experts' group statement of the Working Group on Noninvasive Electrocardiology and Telemedicine of*]. *Kardiol Pol*, 2016. **74**(8): p. 812-9.
2. Chrispin, J., et al., *Association of electrocardiographic and imaging surrogates of left ventricular hypertrophy with incident atrial fibrillation: MESA (Multi-Ethnic Study of Atherosclerosis)*. *J Am Coll Cardiol*, 2014. **63**(19): p. 2007-13.
3. Burgos, P.F., et al., *Electrocardiogram Performance in the Diagnosis of Left Ventricular Hypertrophy in Hypertensive Patients With Left Bundle Branch Block*. *Arq Bras Cardiol*, 2017. **108**(1): p. 47-52.
4. Buchner, S., et al., *Electrocardiographic diagnosis of left ventricular hypertrophy in aortic valve disease: evaluation of ECG criteria by cardiovascular magnetic resonance*. *J Cardiovasc Magn Reson*, 2009. **11**: p. 18.
5. Peguero, J.G., et al., *Electrocardiographic Criteria for the Diagnosis of Left Ventricular Hypertrophy*. *J Am Coll Cardiol*, 2017. **69**(13): p. 1694-1703.
6. Petersen, S.E., et al., *Reference ranges for cardiac structure and function using cardiovascular magnetic resonance (CMR) in Caucasians from the UK Biobank population cohort*. *J Cardiovasc Magn Reson*, 2017. **19**(1): p. 18.
7. Bluemke, D.A., et al., *The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study*. *J Am Coll Cardiol*, 2008. **52**(25): p. 2148-55.
8. Armstrong, A.C., et al., *Left ventricular mass and hypertrophy by echocardiography and cardiac magnetic resonance: the multi-ethnic study of atherosclerosis*. *Echocardiography*, 2014. **31**(1): p. 12-20.
9. Oseni, A.O., et al., *Left ventricular hypertrophy by ECG versus cardiac MRI as a predictor for heart failure*. *Heart*, 2017. **103**(1): p. 49-54.
10. Brumback, L.C., et al., *Body size adjustments for left ventricular mass by cardiovascular magnetic resonance and their impact on left ventricular hypertrophy classification*. *Int J Cardiovasc Imaging*, 2010. **26**(4): p. 459-68.
11. Chirinos, J.A., et al., *Left ventricular mass: allometric scaling, normative values, effect of obesity, and prognostic performance*. *Hypertension*, 2010. **56**(1): p. 91-8.